Back to Search
Start Over
Use of Granulocyte-colony Stimulating Factor During Chemotherapy and Its Association With CA27.29 and Circulating Tumor Cells-Results From the SUCCESS A Trial.
- Source :
-
Clinical breast cancer [Clin Breast Cancer] 2018 Oct; Vol. 18 (5), pp. e1103-e1110. Date of Electronic Publication: 2018 Jun 18. - Publication Year :
- 2018
-
Abstract
- Background: Little is known about the effect of granulocyte colony-stimulating factor (G-CSF) treatment during adjuvant chemotherapy on prognostic markers. The present study explored the association between G-CSF and changes in cancer antigen (CA)27.29 and circulating tumor cell (CTC) levels during therapy.<br />Patients and Methods: A total of 3754 node-positive or high-risk node-negative early-stage breast cancer patients were treated within the SUCCESS-A trial (simultaneous study of gemcitabine-docetaxel combination adjuvant treatment, as well as extended bisphosphonate and surveillance-trial). CA27.29 and CTCs were determined before the start and within 6 weeks after the end of chemotherapy.<br />Results: Overall, 1324 of the 2646 patients (50.0%) available for analysis had ≥ 1 G-CSF applications during chemotherapy. G-CSF application was significantly associated with CA27.29 status before and after chemotherapy (χ <superscript>2</superscript>  = 30.6, df = 3; P < .001), because 238 patients (18.0%) with G-CSF treatment but only 146 (11.0%) without G-CSF treatment switched from a negative CA27.29 status before to a positive CA27.29 status after chemotherapy. In addition, patients with G-CSF application showed a significantly greater increase in CA27.29 levels after chemotherapy compared with patients without any G-CSF application during chemotherapy (Mann-Whitney U test; Z = -7.81, P < .001). No significant association was found between G-CSF application and CTC status before or after chemotherapy (χ <superscript>2</superscript>  = 1.2, df = 3; P = .75).<br />Conclusion: Cautious interpretation is needed regarding elevated levels of MUC-1-derived tumor markers such as CA27.29 shortly after adjuvant chemotherapy when G-CSF has been given, because G-CSF treatment was associated with increased CA27.29 levels after chemotherapy.<br /> (Copyright © 2018 Elsevier Inc. All rights reserved.)
- Subjects :
- Adult
Aged
Antigens, Tumor-Associated, Carbohydrate blood
Biomarkers, Tumor blood
Breast Neoplasms blood
Chemotherapy, Adjuvant methods
Clinical Trials as Topic
Female
Humans
Middle Aged
Retrospective Studies
Young Adult
Antigens, Tumor-Associated, Carbohydrate drug effects
Antineoplastic Combined Chemotherapy Protocols therapeutic use
Breast Neoplasms drug therapy
Granulocyte Colony-Stimulating Factor administration & dosage
Neoplastic Cells, Circulating drug effects
Subjects
Details
- Language :
- English
- ISSN :
- 1938-0666
- Volume :
- 18
- Issue :
- 5
- Database :
- MEDLINE
- Journal :
- Clinical breast cancer
- Publication Type :
- Academic Journal
- Accession number :
- 30017795
- Full Text :
- https://doi.org/10.1016/j.clbc.2018.06.006